Metabolic therapy developer Axcella Health has priced its shares at $20 each in an offering that enabled Nestlé Health Science to exit.
Axcella Health, a US-based metabolic drug developer that counts food and nutritional product supplier Nestlé as an investor, has gone public in a $71.4m initial public offering.
The company issued approximately 3.57 million shares on the Nasdaq Global Market priced at the bottom of the $20 to $22 range it set late last month. Undisclosed existing backers expressed interest in buying up to $39m of shares but Axcella has not revealed whether they did so.
Formerly known as Pronutria…
